The low Fc effector function of IgG4 (which barely mediates ADCC, CDC, or ADCP) gives it a unique advantage in tumor immunotherapy scenarios that focus on blocking target signaling (such as the PD-1/PD-L1 pathway) without relying on immune cell killing [96]. Here, CD274 is linked to neoplasm.